5 reports

  • 5.1 GLOBAL DEPRESSIVE DISORDER MARKET

Various other reasons that can trigger depression are trauma, loss of loved ones, a difficult relationship, or any stressful situation.

  • Depression
  • Mental Health
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.
  • SMALL MOLECULES TO ANTAGONIZE NR2B FOR NEUROPATHIC PAIN
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2019

In May 2007, National Institute of Mental Health (NIMH) initiated a Phase ## Investigation of the antidepressant effects of the selective NR##B antagonist MK-## in major depression.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018
  • SMALL MOLECULES TO ANTAGONIZE NR2B FOR NEUROPATHIC PAIN - DRUG PROFILE

In May 2007, National Institute of Mental Health (NIMH) initiated a Phase ## Investigation of the antidepressant effects of the selective NR##B antagonist MK-## in major depression.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Antipsychotic
  • Clinical Trial
  • Depression
  • Therapy
  • AstraZeneca PLC
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016
  • Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Featured News & Press Releases

The second new collaboration will focus upon a group of novel compounds that target the group ## metabotropic glutamate receptors (mGLUR##/ ##). mGLUR##/ ## antagonists represent novel, potential agents for the treatment of anxiety, depression and other CNS conditions.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.